STOCK TITAN

Phantom unit grant boosts Pfizer (NYSE: PFE) director deferred stake

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Taraporevala Cyrus reported acquisition or exercise transactions in this Form 4 filing.

Pfizer Inc. director Cyrus Taraporevala received a grant of 7,686.539 Phantom Stock Units tied to Pfizer common stock. Each unit represents one phantom share of common stock and was valued at $26.67 per unit for this grant.

The award was granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors as deferred director compensation. These units will be settled in cash or common stock, at the director’s election, after retirement from the Board of Directors. Following this grant, Taraporevala holds a total of 34,826.086 Phantom Stock Units directly.

Positive

  • None.

Negative

  • None.
Insider Taraporevala Cyrus
Role null
Type Security Shares Price Value
Grant/Award Phantom Stock Units 7,686.539 $26.67 $205K
Holdings After Transaction: Phantom Stock Units — 34,826.086 shares (Direct, null)
Footnotes (1)
  1. Each unit represents one phantom share of common stock. Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors.
Phantom Stock Units granted 7,686.539 units Grant to non-employee director on April 23, 2026
Reference value per unit $26.67 per unit Value used for the Phantom Stock Unit grant
Total Phantom Stock Units after grant 34,826.086 units Director’s direct phantom unit holdings following the transaction
Underlying common stock equivalent 7,686.539 shares Each Phantom Stock Unit represents one phantom share of common stock
Phantom Stock Units financial
"Each unit represents one phantom share of common stock."
Phantom stock units are company promises that pay a cash or stock-equivalent award tied to the firm’s share price or value growth, but they do not issue actual shares. Think of them as a bonus check that moves with the stock like a mirror rather than handing over an ownership slice. Investors care because these awards can affect a company’s future cash obligations, executive incentives and reported expenses without causing share dilution.
Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors financial
"Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors."
deferred director's compensation financial
"These units represent deferred director's compensation that are settled in cash or common stock at the director's election..."
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Taraporevala Cyrus

(Last)(First)(Middle)
66 HUDSON BOULEVARD EAST
ATTN: CORPORATE SECRETARY

(Street)
NEW YORK NEW YORK 10001-2192

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Phantom Stock Units(1)04/23/2026A7,686.539(2) (3) (3)Common Stock7,686.539$26.6734,826.086D
Explanation of Responses:
1. Each unit represents one phantom share of common stock.
2. Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
3. These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors.
/s/ Shanice A. Reid, by power of atty., for Cyrus Taraporevala04/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Pfizer (PFE) director Cyrus Taraporevala report?

Cyrus Taraporevala reported receiving 7,686.539 Phantom Stock Units as deferred director compensation. Each unit tracks one share of Pfizer common stock and forms part of his non-employee director compensation package under a Pfizer deferred compensation and unit award plan.

What are Pfizer (PFE) Phantom Stock Units granted to the director?

Phantom Stock Units are bookkeeping units that mirror Pfizer common stock value. For this grant, each unit represents one phantom share of common stock and is settled later in cash or stock, rather than being an immediate open-market share purchase or sale.

Under which plan were the Pfizer (PFE) Phantom Stock Units granted?

The units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. This plan provides deferred compensation to outside directors, using phantom stock units linked to Pfizer’s common shares instead of immediate cash or stock payments.

When will Cyrus Taraporevala’s Pfizer (PFE) Phantom Stock Units be settled?

The Phantom Stock Units will be settled following Taraporevala’s retirement from Pfizer’s Board of Directors. At that time, they are payable in either cash or Pfizer common stock, according to the director’s election, as described in the plan’s terms.

How many Pfizer (PFE) Phantom Stock Units does Cyrus Taraporevala hold after this grant?

After receiving 7,686.539 additional Phantom Stock Units, Taraporevala holds a total of 34,826.086 such units directly. This reflects his accumulated deferred director compensation under Pfizer’s non-employee director deferred compensation and unit award plan.

What was the reference value per Pfizer (PFE) Phantom Stock Unit in this grant?

The grant used a reference value of $26.67 per Phantom Stock Unit. This value helps determine the size of the award for deferred compensation purposes but does not represent an open-market trade executed by the director on the grant date.